Actively Recruiting
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Led by Johnson & Johnson Enterprise Innovation Inc. · Updated on 2026-05-08
30
Participants Needed
16
Research Sites
128 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer of the mouth \& throat).
CONDITIONS
Official Title
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically proven diagnosis of head and neck squamous cell carcinoma in the oral cavity, oropharynx (p16 negative), hypopharynx, or supraglottic larynx
- Stage III, IVA, or IVB disease according to the 8th Edition of AJCC guidelines
- Candidate for definitive concurrent chemoradiation therapy as determined by the investigator and local guidelines
- At least one target lesion (primary tumor or involved lymph node) measurable by RECIST v1.1
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
You will not qualify if you...
- Primary tumor starting in nasopharynx, paranasal sinuses, salivary glands, thyroid gland, parathyroid gland, skin, or unknown primary site
- Non-squamous cell histology
- Stages 0, I, II, or IVC HNSCC; loco-regionally recurrent HNSCC; or synchronous second primary HNSCC within 2 months
- Not eligible to receive cisplatin chemotherapy
- Known or suspected allergies, hypersensitivity, or intolerance to JNJ-90301900 or its excipients
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 16 locations
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Actively Recruiting
2
City of Hope
Duarte, California, United States, 91010
Actively Recruiting
3
Mayo Clinic
Jacksonville, Florida, United States, 32224
Actively Recruiting
4
Moffit Cancer center
Tampa, Florida, United States, 33612
Actively Recruiting
5
Emory University
Atlanta, Georgia, United States, 30308
Actively Recruiting
6
Boston Medical Center
Boston, Massachusetts, United States, 02118
Actively Recruiting
7
Montefiore Medical Center
The Bronx, New York, United States, 10467
Actively Recruiting
8
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27514
Actively Recruiting
9
Hopital De La Cavale Blanche
Brest, France, 29200
Actively Recruiting
10
Centre Oscar Lambret
Lille, France, 59000
Actively Recruiting
11
Hopital La Timone
Marseille, France, 13385
Actively Recruiting
12
Centre Henri Becquerel
Rouen, France, 76038
Actively Recruiting
13
Gustave Roussy
Villejuif, France, 94805
Actively Recruiting
14
Hiroshima University Hospital
Hiroshima, Japan, 734 8551
Actively Recruiting
15
Aichi Cancer Center
Nagoya, Japan, 464-8681
Actively Recruiting
16
Tokyo Medical University Hospital
Tokyo, Japan, 160-0023
Actively Recruiting
Research Team
S
Study Contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here